GO:0004508 steroid 17-alpha-monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004508 (steroid 17-alpha-monooxygenase activity) is a cytochrome P450 monooxygenase activity that converts C21 steroids to 17alpha-hydroxy-C21 steroids using O2 and electrons from NADPH via P450 oxidoreductase.
• The enzyme responsible in humans is CYP17A1 (P450c17), which also catalyzes 17,20-lyase activity, making it a key branch-point regulator of glucocorticoid, androgen, and estrogen synthesis.
• Defects in 17alpha-hydroxylase/17,20-lyase cause disorders of sex development and hypertension, and the activity is a target in prostate cancer and Cushing syndrome pharmacology.
• Regulation occurs at transcriptional, post-translational (phosphorylation, redox partner availability), and substrate/product inhibition levels.
• Experimental study uses steroid conversion assays, microsomal P450 reconstitution, cell models (Leydig, granulosa, placental), and CRISPR-engineered cell lines.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of CYP17A1 function and its disease variants.
Description
Steroid 17-alpha-monooxygenase activity (GO:0004508) is a molecular function defined as the catalysis of the reaction: a C21-steroid + O2 + reduced [NADPH--hemoprotein reductase] = a 17alpha-hydroxy-C21-steroid + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. This activity is central to steroidogenesis because it introduces a hydroxyl group at carbon 17 of the steroid scaffold, a prerequisite for subsequent 17,20-lyase action and androgen production. In humans, this activity is carried by CYP17A1 (also called P450c17), a microsomal cytochrome P450 enzyme expressed in adrenal cortex, gonads, and placenta. Researchers study GO:0004508 to understand how the body partitions steroid precursors toward glucocorticoids versus sex steroids, and how perturbations lead to endocrine disease.
steroid 17-alpha-monooxygenase activity At A Glance
| GO ID | GO:0004508 |
|---|---|
| GO term | steroid 17-alpha-monooxygenase activity |
| Ontology | molecular_function |
| Synonym | steroid 17-alpha-hydroxylase activity; 17alpha-hydroxylase-C17,20 lyase activity; cytochrome P450 CYP17; steroid 17-alpha-hydroxylase/17,20 lyase activity |
| Major function | 17alpha-hydroxylation of C21 steroids using O2 and NADPH-derived electrons |
| Cofactor | Heme iron in cytochrome P450; NADPH-hemoprotein reductase (P450 oxidoreductase) as electron donor |
| Substrate class | C21 steroids such as pregnenolone and progesterone |
| Product class | 17alpha-hydroxy-C21 steroids such as 17alpha-hydroxypregnenolone and 17alpha-hydroxyprogesterone |
| Representative enzyme | CYP17A1 (P450c17) in humans |
What Is GO:0004508?
In plain terms, steroid 17-alpha-monooxygenase activity is the enzyme function that adds an oxygen atom to carbon 17 of a C21 steroid, using molecular oxygen and electrons delivered by a NADPH-dependent reductase partner. The official QuickGO definition states: Catalysis of the reaction: a C21-steroid + O2 + reduced [NADPH--hemoprotein reductase] = a 17alpha-hydroxy-C21-steroid + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. This activity is synonymous with steroid 17-alpha-hydroxylase activity and is often studied together with the associated 17,20-lyase activity of the same enzyme.
Why Is steroid 17-alpha-monooxygenase activity Important in Cell Biology?
GO:0004508 is a gatekeeping activity in steroid hormone biosynthesis: it determines whether steroid precursors are routed toward mineralocorticoids/glucocorticoids or toward androgens and estrogens. Because the same enzyme also performs 17,20-lyase chemistry, changes in its activity alter the balance of cortisol, androgens, and estrogens, with direct consequences for sexual development, blood pressure, and cancer biology. Consequently, measuring and manipulating this activity is essential for endocrine research and for developing drugs that selectively modulate CYP17A1.
• Controls the branch point between glucocorticoid and sex steroid synthesis.
• Loss-of-function causes 17alpha-hydroxylase/17,20-lyase deficiency, a form of disorders of sex development with hypertension.
• Increased 17,20-lyase flux contributes to androgen excess in conditions such as prostate cancer and polycystic ovary syndrome.
• Pharmacologic inhibition (e.g., abiraterone) is used to suppress androgen synthesis in prostate cancer.
• Provides a model for cytochrome P450 electron transfer from NADPH via P450 oxidoreductase.
• Regulated by substrate availability, product inhibition, and redox partner levels.
• Studied in ovarian granulosa cells, Leydig cells, and placenta to understand tissue-specific steroidogenesis.
• Serves as a target for structure-function studies of serine residues and reductase interactions.
Molecular Mechanism of steroid 17-alpha-monooxygenase activity
Substrate binding and heme activation
In simple terms: The enzyme grabs a steroid and activates oxygen using its heme iron.
CYP17A1 binds a C21 steroid such as pregnenolone or progesterone in its active site, where the heme iron coordinates molecular oxygen. The heme is reduced by electrons delivered from NADPH via P450 oxidoreductase, enabling oxygen activation and insertion of a hydroxyl group at C17. This step is the defining chemistry of GO:0004508.
Electron transfer from NADPH-hemoprotein reductase
In simple terms: A partner protein supplies electrons so the reaction can proceed.
The reaction requires reduced [NADPH--hemoprotein reductase] as the electron donor. Studies of P450c17 show that P450 oxidoreductase contributes to both 17alpha-hydroxylase and 17,20-lyase activities, and that mutations in the reductase or in CYP17A1 (e.g., serine106) alter catalytic efficiency. This dependence on a redox partner is a core feature of the GO:0004508 definition.
17alpha-hydroxylation and product formation
In simple terms: The steroid gets an OH group at carbon 17, forming a 17alpha-hydroxy product.
The immediate product of GO:0004508 is a 17alpha-hydroxy-C21-steroid, such as 17alpha-hydroxypregnenolone or 17alpha-hydroxyprogesterone. These products are substrates for subsequent 17,20-lyase chemistry (also catalyzed by CYP17A1) that yields androgen precursors, linking GO:0004508 to androgen synthesis.
Product inhibition and local regulation
In simple terms: The product can slow down the enzyme, providing a feedback brake.
Endogenous 17alpha-hydroxyprogesterone can inhibit steroid 17-alpha-monooxygenase in microsomes and isolated Leydig cells, indicating product inhibition as a local regulatory mechanism. This feedback may help buffer flux through the pathway under conditions of high steroid output.
Tissue-specific expression and regulation
In simple terms: Different tissues tune how much of this activity they use.
Steroid 17-alpha-hydroxylase activity is regulated in ovarian granulosa cells and in ovine placenta by hormonal and glucocorticoid signals, illustrating tissue-specific control. In adrenarche, changes in CYP17A1 expression and electron transfer influence the shift toward androgen production.
Key Genes Involved in GO:0004508 steroid 17-alpha-monooxygenase activity
The following genes and proteins are directly implicated in steroid 17-alpha-monooxygenase activity (GO:0004508) or its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP17A1 | Encodes P450c17, the enzyme carrying 17alpha-hydroxylase and 17,20-lyase activities | Central to GO:0004508; mutations cause 17alpha-hydroxylase/17,20-lyase deficiency |
| POR | Encodes P450 oxidoreductase, the NADPH-hemoprotein reductase that donates electrons | Required for catalytic activity; mutations affect both hydroxylase and lyase reactions |
| FDX1 | Ferredoxin, electron carrier in mitochondrial P450 systems | Supports related steroidogenic P450 reactions; context for redox biology |
| FDXR | Ferredoxin reductase, provides electrons to mitochondrial P450s | Relevant to steroidogenic electron transfer networks |
| STAR | Cholesterol transport into mitochondria | Upstream of steroid precursor supply for 17alpha-hydroxylation |
| CYP11A1 | Cholesterol side-chain cleavage enzyme | Generates pregnenolone, the substrate for 17alpha-hydroxylation |
| HSD3B2 | 3beta-hydroxysteroid dehydrogenase | Converts pregnenolone to progesterone, another substrate for CYP17A1 |
| CYP21A2 | 21-hydroxylase | Competes for progesterone/17alpha-hydroxyprogesterone in glucocorticoid synthesis |
| CYP11B1 | 11beta-hydroxylase | Downstream of 17alpha-hydroxyprogesterone in cortisol synthesis |
| CYP19A1 | Aromatase | Converts androgens to estrogens; linked to 17alpha-hydroxylase flux |
| NR5A1 | SF-1, transcription factor regulating steroidogenic genes | Controls CYP17A1 expression in adrenal and gonadal tissues |
| NR0B1 | DAX-1, repressor of steroidogenic genes | Modulates CYP17A1 transcription |
| LHCGR | LH receptor | Hormonal input that regulates gonadal steroidogenesis |
| INSL3 | Leydig cell marker | Context for Leydig cell steroidogenic studies |
| SULT2A1 | Steroid sulfotransferase | Modifies steroid products; relevant to placental steroid metabolism |
| STS | Steroid sulfatase | Regulates sulfated steroid pools in placenta |
| AKR1C3 | 17beta-hydroxysteroid dehydrogenase type 5 | Contributes to androgen synthesis downstream of CYP17A1 |
| SRD5A2 | 5alpha-reductase | Converts testosterone to DHT; downstream of androgen synthesis |
How Is steroid 17-alpha-monooxygenase activity Regulated?
Steroid 17-alpha-monooxygenase activity is regulated at multiple levels. Transcriptionally, CYP17A1 expression is controlled by steroidogenic transcription factors such as NR5A1 and NR0B1 in adrenal and gonadal tissues. Post-translationally, the availability of P450 oxidoreductase and the efficiency of electron transfer modulate both 17alpha-hydroxylase and 17,20-lyase activities, as shown by studies of serine106 and reductase contributions. Locally, product inhibition by 17alpha-hydroxyprogesterone can restrain enzyme activity in Leydig cells and microsomes. Hormonal signals, including glucocorticoids and gonadotropins, regulate activity in placenta and ovarian granulosa cells. Together, these layers tune flux through GO:0004508 to meet endocrine demands.
steroid 17-alpha-monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP17A1 | 17alpha-hydroxylase/17,20-lyase deficiency; disorders of sex development with hypertension | CRISPR knockout or point-mutation in adrenal/gonadal cell lines; steroid profiling |
| CYP17A1 | Prostate cancer androgen synthesis | Knockout or overexpression in prostate cancer cell lines; androgen assays |
| POR | P450 oxidoreductase deficiency affecting steroidogenesis | Point-mutation knock-in in steroidogenic cells; electron transfer assays |
| CYP17A1 | Adrenarche and androgen excess | Overexpression or knock-in in adrenal cell models; steroid metabolomics |
| CYP17A1 | Placental steroidogenesis and parturition | Knockout or knockdown in placental trophoblast models; hormone assays |
17alpha-hydroxylase/17,20-lyase deficiency
Loss-of-function variants in CYP17A1 cause combined 17alpha-hydroxylase/17,20-lyase deficiency, a rare form of disorders of sex development characterized by impaired sex steroid synthesis, hypertension, and hypokalemia due to mineralocorticoid excess. The clinical phenotype reflects the loss of GO:0004508 activity in both adrenal and gonadal tissues.
Androgen-dependent cancers
Because 17,20-lyase activity downstream of 17alpha-hydroxylation contributes to androgen synthesis, CYP17A1 is a therapeutic target in prostate cancer. Pharmacologic inhibition of this activity reduces androgen production and is used clinically. This links GO:0004508 to cancer endocrinology.
Adrenarche and androgen excess
Changes in CYP17A1 expression and electron transfer during adrenarche influence the shift toward adrenal androgen production, and dysregulation may contribute to androgen excess conditions. Understanding GO:0004508 helps explain how the adrenal cortex alters steroid output with age.
Placental steroidogenesis and parturition
Ovine placental steroid 17-alpha-hydroxylase activity is regulated by glucocorticoids and changes during parturition, suggesting roles in pregnancy and labor. These studies provide comparative endocrine models for GO:0004508.
From steroid 17-alpha-monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP17A1 abolish 17alpha-hydroxylase activity? | CRISPR knockout in steroidogenic cell lines (e.g., adrenal or Leydig) |
| How do disease-associated point mutations affect catalysis? | Point-mutation knock-in of CYP17A1 variants; steroid conversion assays |
| Can we tag CYP17A1 to track localization? | Tagged knock-in (e.g., fluorescent or epitope tag) in steroidogenic cells |
| Does overexpression increase androgen flux? | Overexpression of CYP17A1 in cell models; androgen measurement |
| How does P450 oxidoreductase level affect activity? | Knockout or overexpression of POR in reconstituted systems |
| What is the role of product inhibition in Leydig cells? | Isolated Leydig cell models with 17alpha-hydroxyprogesterone treatment |
How to Study the steroid 17-alpha-monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Steroid conversion assay | 17alpha-hydroxylase activity on C21 substrates | Enzyme kinetics and inhibitor testing |
| LC-MS/MS steroid profiling | Levels of 17alpha-hydroxy products and downstream steroids | Cell and tissue steroidogenesis studies |
| Reconstituted P450 system | Electron transfer and catalytic efficiency | Mechanistic studies of CYP17A1 and POR |
| qPCR / RNA-seq | CYP17A1 and steroidogenic gene expression | Tissue-specific regulation studies |
| Western blot / immunodetection | CYP17A1 protein levels | Expression and stability analysis |
| CRISPR knockout | Loss-of-function phenotype | Causal testing in cell models |
| Point-mutation knock-in | Effect of disease variants | Genotype-phenotype correlation |
| Overexpression | Gain-of-function steroid output | Androgen excess modeling |
Steroid conversion assays
Enzymatic activity of GO:0004508 is measured by incubating microsomes or cell lysates with C21 steroid substrates and NADPH, then quantifying 17alpha-hydroxy products by chromatography or immunoassay. These assays directly report the catalytic function defined by the GO term.
Reconstitution with P450 oxidoreductase
Purified CYP17A1 can be reconstituted with NADPH-hemoprotein reductase to study electron transfer and the contributions of specific residues such as serine106 to 17alpha-hydroxylase and 17,20-lyase activities. This approach isolates the molecular mechanism of GO:0004508.
Cell-based steroidogenesis models
Ovarian granulosa cells, Leydig cells, and placental tissue preparations have been used to measure steroid 17-alpha-hydroxylase activity under hormonal stimulation, providing physiological context. These models capture tissue-specific regulation of the activity.
Genetic and pharmacologic perturbation
CRISPR knockout, point mutation, and overexpression of CYP17A1 or POR allow causal testing of the activity in disease-relevant cells, while pharmacologic inhibitors such as abiraterone probe pathway dependence. Such experiments link GO:0004508 to endocrine phenotypes.
How CRISPR Can Be Used to Study GO:0004508 steroid 17-alpha-monooxygenase activity
Knockout
CRISPR knockout of CYP17A1 or POR in steroidogenic cell lines abolishes or reduces 17alpha-hydroxylase activity, providing a clean loss-of-function model to test the role of GO:0004508 in steroid output and disease phenotypes. Such models are useful for validating inhibitor specificity and pathway flux.
Point Mutation
Point-mutation knock-in of patient-derived CYP17A1 variants (e.g., affecting serine106 or other residues) allows precise testing of how specific amino acid changes alter 17alpha-hydroxylase and 17,20-lyase activities. This connects genotype to the catalytic function defined by GO:0004508.
Knock-in
Tagged knock-in of CYP17A1 (e.g., with fluorescent or epitope tags) enables tracking of enzyme localization and interaction with P450 oxidoreductase in live cells, linking subcellular behavior to GO:0004508 activity. Knock-in of regulatory elements can also probe transcriptional control.
Overexpression
Overexpression of CYP17A1 in cell models increases 17alpha-hydroxylase flux and can model androgen excess states, helping to dissect downstream effects on androgen receptor signaling and proliferation. Overexpression combined with POR modulation tests electron transfer limitation.
How EDITGENE Supports steroid 17-alpha-monooxygenase activity Research
Researchers studying steroid 17-alpha-monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in 17alpha-hydroxylation, androgen synthesis, or endocrine disease. EDITGENE provides CRISPR-based cell model engineering and screening services to enable such causal experiments with reproducible, publication-ready models.
Contact EDITGENE today to design your custom CRISPR model for steroid 17-alpha-monooxygenase activity research.
Frequently Asked Questions About steroid 17-alpha-monooxygenase activity
What is steroid 17-alpha-monooxygenase activity?
It is the enzyme activity defined by GO:0004508 that converts a C21 steroid to a 17alpha-hydroxy-C21 steroid using O2 and electrons from NADPH-hemoprotein reductase.
What gene encodes steroid 17-alpha-monooxygenase activity?
In humans, CYP17A1 encodes P450c17, the enzyme responsible for this activity and for associated 17,20-lyase activity.
What is the difference between 17alpha-hydroxylase and 17,20-lyase?
Both are activities of the same CYP17A1 enzyme; 17alpha-hydroxylase adds an OH at C17, while 17,20-lyase cleaves the side chain to produce androgens.
What diseases are linked to GO:0004508?
Loss of this activity causes 17alpha-hydroxylase/17,20-lyase deficiency, a disorder of sex development with hypertension, and altered activity is relevant to prostate cancer.
How is steroid 17-alpha-monooxygenase activity measured?
It is typically measured by incubating microsomes or cells with C21 steroid substrates and NADPH, then quantifying 17alpha-hydroxy products.
What cofactors are required for steroid 17-alpha-monooxygenase activity?
The reaction requires molecular oxygen and reduced NADPH-hemoprotein reductase (P450 oxidoreductase) to supply electrons to the heme iron.
Can CRISPR be used to study CYP17A1 function?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of CYP17A1 function and disease variants.
Is steroid 17-alpha-monooxygenase activity regulated by product inhibition?
Yes, endogenous 17alpha-hydroxyprogesterone can inhibit the activity in microsomes and Leydig cells, providing local feedback.
Where is steroid 17-alpha-monooxygenase activity expressed?
It is expressed in steroidogenic tissues including adrenal cortex, gonads, and placenta, with tissue-specific regulation.
Why is GO:0004508 important for drug development?
Because it controls androgen synthesis, inhibiting this activity is a strategy in prostate cancer and other androgen-dependent conditions.
Conclusion
Steroid 17-alpha-monooxygenase activity (GO:0004508) is a pivotal cytochrome P450 function that determines the fate of steroid precursors and governs the balance between glucocorticoids and sex steroids. Its study spans enzymology, endocrinology, and disease genetics, with CYP17A1 and its redox partner POR at the center. CRISPR-based cell models now make it possible to dissect this activity with unprecedented precision, accelerating both mechanistic insight and therapeutic development.
References
- 1. Yanase T. 1995. 17 alpha-Hydroxylase/17,20-lyase defects.. J Steroid Biochem Mol Biol 53(1-6):153-7 PMID: 7626447
- 2. Auchus RJ. 2017. Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic.. J Steroid Biochem Mol Biol 165(Pt A):71-78 PMID: 26862015
- 3. Johnson DC et al.. 1981. Steroid 17 alpha-hydroxylase activity of ovarian granulosa cells from hypophysectomized immature rats treated with pregnant mare's serum gonadotropin (PMS).. Steroids 38(5):581-92 PMID: 6798717
- 4. Lin D et al.. 1993. Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase.. Endocrinology 132(6):2498-506 PMID: 8504753
- 5. Mason JI et al.. 1989. Ovine placental steroid 17 alpha-hydroxylase/C-17,20-lyase, aromatase and sulphatase in dexamethasone-induced and natural parturition.. J Endocrinol 122(1):351-9 PMID: 2788698
- 6. France JT et al.. 1988. The regulation of ovine placental steroid 17 alpha-hydroxylase and aromatase by glucocorticoid.. Mol Endocrinol 2(3):193-9 PMID: 3135486
- 7. Kühn-Velten N et al.. 1984. Product inhibition of steroid-17 alpha-monooxygenase by endogenous 17 alpha-hydroxyprogesterone in microsomes and isolated Leydig cells from rat testis.. J Steroid Biochem 21(6):697-700 PMID: 6335539
- 8. Miller WL. 2009. Androgen synthesis in adrenarche.. Rev Endocr Metab Disord 10(1):3-17 PMID: 18821018
